Cingulate (CING) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cingulate (CING) has outperformed Oncolytics Biotech (ONCY) over the past year, gaining 17.3% versus a loss of 57.5%. Oncolytics Biotech is the larger company by market cap ($71.4 million vs $71.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | ONCY |
|---|---|---|
| Share price | $4.88 | $0.5444 |
| Market cap | $70.96M | $71.38M |
| 1-day change | +0.21% | -8.63% |
| YTD return | +12.21% | -37.43% |
| 1-year return | +17.35% | -57.47% |
| 5-year return | — | -75.48% |
| EPS (TTM) | $-3.51 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.89 | $1.32 |
| 52-week low | $3.16 | $0.54 |
| Distance from 52-week high | -58.96% | -58.76% |
| Analyst consensus | none | buy |
| Avg. price target upside | +334.43% | +662.31% |
| Average volume | 139.16K | 1.08M |
| Shares outstanding | 14.54M | 131.12M |
| Employees | 14 | 29 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed ONCY by 74.8 percentage points over the past year.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Healthcare · Biotechnology · 14 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Healthcare · Biotechnology · 29 employees
CING vs ONCY FAQ
Which is bigger, Cingulate or Oncolytics Biotech?
Oncolytics Biotech (ONCY) is larger, with a market capitalization of $71.38M compared with $70.96M for Cingulate (CING).
Which stock has performed better over the past year, CING or ONCY?
CING returned +17.35% over the past 12 months, compared with -57.47% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.